Form 4: Acrivon Therapeutics COO Reports Tax Withholding Transaction
SEC Form 4 Filing
Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On August 14, 2024, Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on SEC Form 4.
- The transaction involved the withholding of 613 shares of common stock by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- The price per share for the withholding was $7.02.
- Following the transaction, Devroe beneficially owns 68,484 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to tax withholding, which is neutral in sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax withholding procedure related to equity compensation.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of transaction (share withholding for tax obligations). |
| 08/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.